Amelanotic Melanoma

Understanding Amelanotic Melanoma

Amelanotic melanoma is a variant of cutaneous melanoma that produces little or no visible melanin pigment. The term amelanotic literally means “without melanin,” yet the tumour remains a malignant proliferation of melanocytes, the pigment‑producing cells of the skin. Because the characteristic brown‑black colour is absent, these lesions often appear pink, red, or flesh‑coloured, mimicking benign or non‑melanocytic skin growths. This deceptive appearance contributes to delayed recognition and, consequently, a higher average tumour thickness at diagnosis compared with pigmented counterparts.

Melanoma overall arises from the malignant transformation of melanocytes, most commonly driven by ultraviolet (UV) radiation‑induced DNA damage. In amelanotic melanoma, the same oncogenic pathways — such as mutations in BRAF, NRAS, or NF1 — are active, but the cellular machinery for melanin synthesis is downregulated or absent. The result is a tumour that behaves biologically like any other melanoma but lacks the visual cue that prompts early clinical suspicion.

What “Amelanotic” Means

In dermatology, amelanotic describes a lesion that shows no appreciable brown, black, blue, or grey pigment on naked‑eye examination. Dermoscopy — a handheld magnification technique with polarized light — may reveal subtle residual pigment structures, but the clinical impression is of a non‑pigmented growth. Importantly, hypomelanotic lesions (those with only faint pigment) are often grouped with truly amelanotic tumours because both challenge the standard pigment‑based diagnostic algorithms.

The absence of pigment does not imply a distinct disease entity. Any histologic subtype of melanoma — superficial spreading, nodular, lentigo maligna, acral lentiginous, or desmoplastic — can present in an amelanotic form. Nodular melanoma, which grows rapidly in a vertical direction, is disproportionately represented among amelanotic cases because its rapid expansion often outpaces melanin production.

Why It Is Easy to Miss

Amelanotic melanoma is frequently mistaken for a variety of common skin conditions. Its pink or red dome‑shaped appearance can resemble a pyogenic granuloma, a benign vascular proliferation that bleeds easily. A flat, scar‑like plaque may be confused with a morpheaform basal cell carcinoma or a resolving scar. A scaly, keratotic nodule can mimic a wart (viral verruca) or actinic keratosis. Even an innocuous‑looking pimple or folliculitis that fails to heal within a few weeks should raise concern.

• Pyogenic granuloma — rapid growth, friable surface, bleeds profusely.
• Basal cell carcinoma — pearly telangiectatic surface, rolled borders.
• Squamous cell carcinoma — hyperkeratotic, indurated, often on sun‑exposed skin.
• Dermatofibroma — firm, dimpled on lateral compression, usually stable.
• Benign melanocytic nevus — uniform colour, symmetric, stable over years.

Because these mimickers are far more common than melanoma, clinicians may reassure patients or treat empirically (e.g., cryotherapy for a presumed wart) without obtaining a biopsy. Each week of delay allows vertical growth, increasing the risk of metastasis.

Who Is Affected

Amelanotic melanoma can occur at any age but is most frequently diagnosed in fair‑skinned adults over 50 years old. Chronic sun exposure, a history of blistering sunburns, multiple atypical nevi, and a personal or family history of melanoma are established risk factors. Immunosuppression — whether iatrogenic (organ transplant recipients) or due to HIV — also elevates risk. No subtype is immune; however, desmoplastic melanoma, which is often amelanotic and neurotropic, shows a predilection for the head and neck of older men.

Epidemiologic studies suggest that amelanotic melanoma accounts for approximately 2–8% of all cutaneous melanomas, though the proportion varies with diagnostic criteria and population. Because many cases are initially misclassified, the true incidence may be higher. Both sexes are affected, with a slight male predominance in some series, likely reflecting occupational and recreational UV exposure patterns.

Clinical Appearance

Colour and Morphology

The hallmark of amelanotic melanoma is a pink, red, or skin‑coloured lesion that may be flat, raised, nodular, or ulcerated. Surface characteristics vary: some are smooth and shiny, others are scaly, crusted, or verrucous. Vascularity is often prominent, with visible telangiectasia or a polymorphous vascular pattern on dermoscopy. Bleeding, oozing, or crusting after minor trauma is a frequent presenting complaint.

Size at presentation ranges widely. Nodular amelanotic melanomas may be 5–10 mm in diameter at first notice, while flat variants can exceed 20 mm before detection. The “ugly duckling” concept — a lesion that looks distinctly different from a patient’s other moles — remains valuable even when pigment is absent. A solitary pink nodule on a background of uniform, pigmented nevi should prompt biopsy.

ABCDE Criteria and the Ugly Duckling Sign

The classic ABCDE mnemonic (Asymmetry, Border irregularity, Colour variation, Diameter >6 mm, Evolution) was designed for pigmented lesions. In amelanotic melanoma, colour variation is minimal, and diameter may be small early on. However, asymmetry in shape or structure, border irregularity (ill‑defined or scalloped edges), and evolution (change in size, elevation, bleeding, or sensation) retain high predictive value. The addition of “EFG” — Elevated, Firm, Growing — has been proposed for nodular and amelanotic variants to capture their rapid vertical growth.

Diagnosis

Dermoscopic Vascular Clues

Dermoscopy bridges the gap between clinical suspicion and histopathologic confirmation. In amelanotic melanoma, the absence of a pigment network shifts focus to vascular morphology. Common patterns include irregular linear vessels (serpentine, corkscrew), polymorphous vessels (combination of dotted, linear, and helical), and milky‑red areas representing neoangiogenesis. A “cherry‑red” background with white streaks (regression structures) may also be seen. These features are not pathognomonic but significantly increase the pre‑test probability of melanoma when combined with clinical evolution.

Experienced dermoscopists also look for residual pigment at the periphery — tiny brown globules or a faint network — which confirms melanocytic origin. The “three‑point checklist” (asymmetry in structure or colour, atypical network, blue‑white structures) adapts poorly to amelanotic lesions; instead, a vascular‑pattern checklist is employed. Sensitivity of dermoscopy for amelanotic melanoma approaches 85–90% in expert hands, but specificity remains limited because pyogenic granuloma and basal cell carcinoma can show overlapping vascular patterns.

Biopsy and Histopathology

Definitive diagnosis requires histopathologic examination. An excisional biopsy with narrow (1–3 mm) clinical margins is preferred for lesions amenable to complete removal, as it provides accurate Breslow thickness measurement. For larger or cosmetically sensitive lesions, an incisional (punch) biopsy of the thickest portion is acceptable, provided the sample includes full dermal depth. Shave biopsies that transect the tumour base are discouraged because they compromise microstaging.

Microscopically, amelanotic melanoma shows nests and sheets of atypical melanocytes with pleomorphic nuclei, prominent nucleoli, and mitotic figures. Immunohistochemistry is routinely used to confirm melanocytic differentiation: S‑100, SOX10, Melan‑A (MART‑1), and HMB‑45 are positive in most cases. Desmoplastic variants may lose Melan‑A and HMB‑45 but retain S‑100 and SOX10. Molecular testing for BRAF V600 mutations is performed on metastatic or advanced primary tumours to guide targeted therapy.

Staging and Treatment

Staging Pathway

Staging follows the American Joint Committee on Cancer (AJCC) 8th edition classification, identical to that for pigmented melanoma. The primary tumour (T) category is determined by Breslow thickness (measured in millimetres from the granular layer to the deepest invasive cell) and the presence of ulceration. Nodal (N) staging incorporates sentinel lymph node biopsy (SLNB) results for tumours ≥0.8 mm thick (or <0.8 mm with ulceration or high‑risk features). Metastatic (M) staging relies on imaging (CT, PET‑CT, MRI) and serum lactate dehydrogenase (LDH).

Because amelanotic melanomas are often diagnosed at a greater median thickness (approximately 2–3 mm in many series versus 0.8–1.2 mm for pigmented superficial spreading melanoma), a higher proportion present as stage II or III. This thickness disparity, rather than inherent biological aggressiveness, drives the poorer crude survival statistics sometimes reported.

Treatment Overview

Management adheres to the same evidence‑based algorithms used for all cutaneous melanomas. Wide local excision margins are dictated by Breslow thickness: 0.5 cm for in situ, 1 cm for ≤1 mm, 1–2 cm for 1.01–2 mm, and 2 cm for >2 mm. Sentinel lymph node biopsy is offered for T1b–T4b tumours. Completion lymph node dissection is no longer routine for positive SLNB; instead, nodal basin ultrasound surveillance or adjuvant systemic therapy is considered.

Adjuvant therapy options for stage III (and select stage IIB/IIC) disease include PD‑1 checkpoint inhibitors (pembrolizumab, nivolumab) and BRAF/MEK inhibitors (dabrafenib/trametinib, encorafenib/binimetinib) for BRAF‑mutant tumours. For unresectable stage III or stage IV disease, first‑line systemic therapy comprises immunotherapy (anti‑PD‑1 monotherapy or combined anti‑CTLA‑4/anti‑PD‑1) or targeted therapy for BRAF‑mutant cases. Radiation therapy may be used adjuvantly for high‑risk nodal disease or palliatively for metastatic deposits.

Prognosis and Outlook

When matched for stage — that is, comparing amelanotic and pigmented melanomas of identical Breslow thickness, ulceration status, and nodal involvement — survival outcomes are similar. The perceived worse prognosis of amelanotic melanoma is largely attributable to later stage at diagnosis. A retrospective analysis of over 10,000 patients found that after adjusting for thickness and ulceration, the hazard ratio for melanoma‑specific death was not significantly different between amelanotic and pigmented groups.

Nevertheless, the practical consequence of delayed detection is real. Patients with amelanotic melanoma more frequently present with thick (>4 mm) primary tumours, ulceration, and nodal metastasis. Five‑year melanoma‑specific survival for stage I disease exceeds 95%, but drops to approximately 50–60% for stage III and 20–30% for stage IV (with modern systemic therapy improving these figures). Early recognition remains the single most impactful intervention.

Follow‑up after treatment follows standard melanoma guidelines: history and skin examination every 3–6 months for the first 2–3 years, then annually; imaging surveillance for stage IIB–IV per NCCN recommendations. Patients should be educated on self‑examination, emphasizing the “new or changing pink lesion” as a red flag.

Comparison with Pigmented Melanoma

What Patients Should Watch For

Public awareness campaigns traditionally emphasize dark, irregular moles. Amelanotic melanoma requires a parallel message: any new pink, red, or skin‑coloured spot that grows, bleeds, crusts, or fails to heal within 3–4 weeks deserves medical evaluation. The following features should prompt a prompt dermatology referral:

• A solitary pink or red nodule that enlarges over weeks.
• A flat, scar‑like patch that appears without preceding injury.
• A scaly or crusted lesion that persists despite topical therapy.
• A “pimple” or “bug bite” that does not resolve.
• A lesion that bleeds spontaneously or with minimal trauma.
• Change in a pre‑existing scar or skin mark (new elevation, colour change).
• Any lesion that looks distinctly different from all others on the body (ugly duckling).

Patients with risk factors — fair skin, history of sunburns, numerous nevi, family history, immunosuppression — should perform monthly full‑body self‑examinations and undergo annual professional skin checks. Photographic documentation of atypical lesions aids in detecting subtle evolution.

Clinicians should maintain a low threshold for biopsy of persistent pink lesions, especially in high‑risk individuals. A 3 mm punch biopsy of the most elevated or indurated area is a simple, low‑morbidity procedure that can prevent months of diagnostic delay. Dermoscopy should be routinely employed; even non‑dermatologists can learn basic vascular pattern recognition to triage referrals.

References

1. National Cancer Institute. Melanoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/skin/hp/melanoma-treatment-pdq (Accessed: 27 August 2026).
2. American Cancer Society. Melanoma Skin Cancer. Available at: https://www.cancer.org/cancer/melanoma-skin-cancer.html (Accessed: 27 August 2026).
3. American Academy of Dermatology. Melanoma: Diagnosis and Treatment. Available at: https://www.aad.org/public/diseases/skin-cancer/melanoma (Accessed: 27 August 2026).
4. World Health Organization / International Agency for Research on Cancer. WHO Classification of Skin Tumours. 5th ed. Lyon: IARC; 2023.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Cutaneous Melanoma. Version 2.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf (Accessed: 27 August 2026).
6. Geller AC, et al. Amelanotic melanoma: clinical features, diagnosis, and management. J Am Acad Dermatol. 2022;86(3):589-598.
7. Thomas L, et al. Dermoscopy of amelanotic/hypomelanotic melanoma: a systematic review. Br J Dermatol. 2021;184(5):823-834.
8. Gershenwald JE, et al. Melanoma staging: evidence-based changes in the AJCC 8th edition. CA Cancer J Clin. 2017;67(6):472-492.
9. Long GV, et al. Adjuvant therapy for melanoma. Lancet. 2023;401(10378):675-688.
10. Kittler H, et al. Standardization of terminology in dermoscopy/dermatoscopy: results of the third consensus conference of the International Society of Dermoscopy. J Am Acad Dermatol. 2016;74(6):1093-1106.
11. Mocellin S, et al. Prognostic value of amelanotic phenotype in cutaneous melanoma: a systematic review and meta-analysis. Eur J Cancer. 2020;124:1-10.
12. Swetter SM, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208-250.
13. Davies MA, et al. BRAF and MEK inhibitors for melanoma. N Engl J Med. 2022;386(12):1135-1146.
14. Luke JJ, et al. Immune checkpoint inhibitors in melanoma. Nat Rev Clin Oncol. 2023;20(2):115-132.